Therapeutic agent of uremia containing alarin as the main ingredient

Abstract

The present invention relates to a novel use of alarin derived from a splice variant of galanin-like peptide (GALP) RNA and thus having an amino acid sequence similar to that of galanin, with a therapeutic agent of uremia, and the therapeutic agents of uremia according to the present invention include alarin as the main ingredient.

What is claimed is: 
     
         1 . The therapeutic agent of uremia characterized in that the therapeutic agent comprises alarin as a main component. 
     
     
         2 . The therapeutic agent of uremia of  claim 1 , wherein the said alarin is characterized in that it is the human-derived alarin trifluoroacetate salt having the following amino acid sequence:
 H-Ala-Pro-Ala-His-Arg-Ser-Ser-Thr-Phe-Pro-Lys-Trp-Val-Thr-Lys-Thr-Glu-Arg-Gly-Arg-Gln-Pro-Leu-Arg-Ser-OH-trifluoroacetate salt.   
     
     
         3 . The therapeutic agent of uremia of  claim 1 , wherein the said alarin has a molecular weight of 2894.29, characterized in that it has the following molecular formula:
   C 127 H 206 N 43 O 38      
     
     
         4 . The therapeutic agent of uremia of  claim 1 , wherein the said therapeutic agent of uremia is characterized in that it is formulated to be administered from 0.5 mg to 10 mg of alarin per an adult of 60 kg body weight. 
     
     
         5 . The therapeutic agent of uremia of  claim 4 , wherein the said formulation is characterized in that it is an injectable one. 
     
     
         6 . The therapeutic agent of uremia of  claim 4 , wherein the said formulation is characterized in that it is injected by subcutaneous muscle injection.